AtlasLive

Trial landscapes for BD and diligence

One trial, its registry records together.

Atlas shows who else is in an indication, by phase and status, from ClinicalTrials.gov, CTIS and the EU Clinical Trials Register. It groups a trial's records across them as one study, linked only through trial numbers in those records, read by fixed rules.

One study, three registries

What does each registry record for NCT05104866 state?

Four statements from each registry for NCT05104866
Field	ClinicalTrials.govNCT05104866	CTIS2023-509631-37-00	EUCTR8 country records
Phase	Phase 3	Phase 3	Phase 3In all 8
Recruitment status	Active, not recruiting	Not collected yet	CompletedNetherlands. 7 others not mapped, with reasons
Sponsor, as written	AstraZenecaDaiichi Sankyo, collaborator	AstraZeneca AB	AstraZeneca ABItaly writes ASTRAZENECA AB
Enrollment	732 actualWhole trial	None in this release	700 plannedWhole trial. 255 planned, EEA

Data as of 6 Oct 2026. Each registry’s statement is shown as given, side by side. Atlas does not reconcile them. Sources: ClinicalTrials.gov; EU Clinical Trials Register (EudraCT); EU Clinical Trials Information System (CTIS).

One study, in full

Ten records. Every statement, with its source.

This is NCT05104866 as Atlas holds it, with data as of 6 Oct 2026: a Phase 3 study with AstraZeneca as lead sponsor and Daiichi Sankyo named as collaborator, registered in ClinicalTrials.gov, in CTIS and in eight EU country records. Nothing is summarized away. Each value keeps its registry, record, field and state, and every gap says why it is a gap.

Identifiers the records state

NCT number: NCT051048666 statements
EU CT number: 2023-509631-37-001 statement
EudraCT number: 2020-005620-122 statements
Sponsor protocol code: D9268C000018 statements

Membership

10 of 10 records published

Each record links to the study because the record itself says so. No record was linked by similarity.

Coded statements

Each record’s own statement, mapped to a shared taxonomy only through an exact published table. Where no exact mapping exists, the statement stays, with its reason code.

Recruitment status

2 mapped, 7 not mapped, 1 not collected yet, of 10 statements

Each record's own status, normalized where an exact table exists.

Active, not recruitingWhole trialMappedClinicalTrials.govOverall Recruitment Status
CompletedCountry recordMappedEUCTR NLTrial Status
Not mappedCountry recordrecord_transitioned_to_ctr, the record moved to the Clinical Trials RegulationEUCTR BE, DE, FR, HU, IT, PLTrial Status
Not mappedCountry recordongoing_recruitment_not_stated, the record does not state ongoing recruitmentEUCTR ESTrial Status
Not collected yetCTISNot read from CTIS in this release

Phase

10 mapped of 34 statements

Normalized to one phase taxonomy; every statement kept.

Phase 3MappedClinicalTrials.govStudy Phase, item 1
Phase 3MappedCTISTrial phase
Phase 3MappedEUCTR, all 8 country recordsE.7.3 Therapeutic confirmatory (Phase III)

Authorization

10 mapped of 26 statements

Regulator decisions, read from the EU records that state them.

AuthorizedMappedCTISOverall trial status
AuthorizedMappedEUCTR, all 8 country recordsN. Competent Authority Decision
AuthorizedMappedEUCTR ESTrial Status

11 of 11 reported

Names exactly as each record writes them, with their role.

AstraZenecaLead sponsorClinicalTrials.govSponsor
Daiichi SankyoCollaboratorClinicalTrials.govCollaborators, item 1
AstraZeneca ABLead sponsorCTISSponsors, item 1
AstraZeneca ABSponsorEUCTR BE, DE, ES, FR, HU, NL, PLB. Sponsor Information, item 1
ASTRAZENECA ABSponsorEUCTR ITB. Sponsor Information, item 1

Sponsor type

11 mapped of 11

Commercial or non-commercial, where a record says.

CommercialMappedClinicalTrials.govSponsor: Agency Class
CommercialMappedClinicalTrials.govCollaborators, item 1: Agency Class
CommercialMappedCTISSponsors, item 1: Sponsor type
CommercialMappedEUCTR, all 8 country recordsB. Sponsor Information, item 1: B.3.1 and B.3.2 Status of the sponsor

Design

Study type 1 of 10, arm role 2 of 11, intervention type 5 of 14

Study type, arm roles and intervention types, from the registry's own fields.

InterventionalMappedClinicalTrials.govStudy Type
ExperimentalArm roleMappedClinicalTrials.govArms, item 1: Type
Active comparatorArm roleMappedClinicalTrials.govArms, item 2: Type
DrugIntervention type, ×5MappedClinicalTrials.govInterventions, items 1 to 5: Type

Dates, as each record states them

Forty dates across ten records. Actual and estimated stay apart, a month-precision date is never given a day, and a date whose role Atlas does not map is still shown.

40 reported of 67 date statements, 16 flagged and not counted

Actual, or no status statedEstimatedRole not mapped

ClinicalTrials.gov and CTIS
Date	Role, as stated	Record
2021-10-04	First submittedGlobal	ClinicalTrials.gov
2021-10-18	StartActual · Global	ClinicalTrials.gov
2021-11-02	First submitted that met QC criteriaGlobal · Role not mapped	ClinicalTrials.gov
2021-11-03	First postedActual · Global	ClinicalTrials.gov
2022-01-18	Start, EU/EEAEU/EEA	CTIS
2022-01-21	Recruitment startEstimated · EU/EEA	CTIS
2024-07-24	Primary completionActual · Global	ClinicalTrials.gov
2025-08-15	End, EU/EEAEstimated · EU/EEA	CTIS
2025-07-23	Results first submittedGlobal · Role not mapped	ClinicalTrials.gov
2026-02-03	Results first submitted that met QC criteriaGlobal · Role not mapped	ClinicalTrials.gov
2026-02-04	Results first postedActual · Global	ClinicalTrials.gov
2026-07-31	Global endEstimated · Global	CTIS
2026-07	Status verifiedGlobal · Role not mapped	ClinicalTrials.gov
2026-08-05	Last update submittedGlobal · Role not mapped	ClinicalTrials.gov
2026-08-24	Last update postedActual · Global	ClinicalTrials.gov
2026-12-31	CompletionEstimated · Global	ClinicalTrials.gov

EUCTR country records, roles not mapped
Record	First entered	Authority decision	Ethics opinion
EUCTR NLCompetent Authority	2021-10-07	2021-10-07	2021-12-28
EUCTR ESAEMPS	2021-10-06	2022-01-07	2022-01-04
EUCTR BEFPS Health-DGM	2021-10-08	2021-10-29	2022-01-13
EUCTR HUNational Institute of Pharmacy	2021-10-13	2021-12-16	2021-11-11
EUCTR ITItalian Medicines Agency	2021-10-18	2021-12-22	2021-10-20
EUCTR DEPEI	2021-10-28	2022-03-08	2022-06-03
EUCTR PLOffice for Medicinal Products	2021-11-05	2021-12-15	2021-12-09
EUCTR FRANSM	2021-11-25	2022-01-25	2022-02-11

Enrollment, by scope

The whole trial, the EEA and each member state are different questions, so Atlas keeps them apart. Counts are never added across records or scopes, and planned is never read as actual.

24 reported of 26 statements; the Belgian record states no member-state count

Whole trial

ClinicalTrials.gov732 actual
EUCTR, all 8 country records700 planned

EEA

EUCTR, all 8 country records255 planned

Member state

EUCTR PL50 planned
EUCTR HU40 planned
EUCTR IT30 planned
EUCTR ES29 planned
EUCTR DE25 planned
EUCTR FR25 planned
EUCTR NL18 planned

CTIS: no enrollment statement in this release. Belgium: no member-state count stated.

Conditions, as reported

Each text and code a record gives is its own term, never merged. MeSH terms are the ones ClinicalTrials.gov assigns, not the sponsor’s. MedDRA codes appear only as the record gives them. A vocabulary match is a candidate until it is reviewed.

33 reported of 34 condition terms; 19 candidates on 10 terms

Condition textAmbiguous
Breast Cancer
literal_name_candidate, the name matches more than one candidate
- MONDO:0007254 breast cancerMONDO, label and synonym match. Candidate match, not reviewed.
- MONDO:0004989 breast carcinomaMONDO, synonym match. Candidate match, not reviewed.
ClinicalTrials.govConditions, item 1
MeSH term, assigned by ClinicalTrials.govCandidate match, not reviewed
D001943Breast Neoplasms
mesh_exact_target_not_accepted, MeSH match not yet reviewed
- MONDO:0021100 breast neoplasmMONDO, skos:exactMatch. Candidate match, not reviewed.
ClinicalTrials.govCondition MeSH Terms, item 1
MeSH term, assigned by ClinicalTrials.govNot mapped
D009362Neoplasm Metastasis
no_exact_or_candidate_publisher_relationship, no exact or candidate vocabulary relation
ClinicalTrials.govCondition MeSH Terms, item 2
Condition textNot mapped
"Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer that Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy"
no_literal_name_candidate, no vocabulary name matches the text
CTISMedical conditions, item 1
Condition textAmbiguous
Breast Cancer
literal_name_candidate, the name matches more than one candidate
- MONDO:0007254 breast cancerMONDO, label and synonym match. Candidate match, not reviewed.
- MONDO:0004989 breast carcinomaMONDO, synonym match. Candidate match, not reviewed.
EUCTR FRE.1 Medical condition or disease under investigation, item 2
MedDRA codeMapped
10083232Shown as the record gives it, without a label
EUCTR FRE.1 Medical condition or disease under investigation, item 7

MeSH 2026 data courtesy of the U.S. National Library of Medicine (NLM). NLM is not responsible for this product and does not endorse it. Mondo Disease Ontology (Monarch Initiative), release v2026-09-01, CC BY 4.0.

Interventions, as reported

The French EUCTR record names each product three ways: a name, an INN and a CAS number. Each is its own term. A CAS number reaches its candidate by a different route from the name, and where no route exists, Atlas says so.

137 reported of 145 intervention terms; 133 candidates on 133 terms

NameCandidate match, not reviewed
Dato-DXd
intervention_candidates_unaccepted, candidates not yet reviewed
- CHEMBL4297939 DATOPOTAMAB DERUXTECANChEMBL, synonym match. Candidate match, not reviewed.
ClinicalTrials.govInterventions, item 1
NameCandidate match, not reviewed
Datopotamab deruxtecan (Dato-DXd, DS-1062a)
intervention_candidates_unaccepted, candidates not yet reviewed
No candidate proposed.
ClinicalTrials.govInterventions, item 1
NameCandidate match, not reviewed
Datopotamab deruxtecan
intervention_candidates_unaccepted, candidates not yet reviewed
- CHEMBL4297939 DATOPOTAMAB DERUXTECANChEMBL, label and synonym match. Candidate match, not reviewed.
CTISProducts, item 6
INNCandidate match, not reviewed
Datopotamab deruxtecan
intervention_candidates_unaccepted, candidates not yet reviewed
- CHEMBL4297939 DATOPOTAMAB DERUXTECANChEMBL, label and synonym match. Candidate match, not reviewed.
EUCTR FRD. IMP Identification, item 1
CASCandidate match, not reviewed
2238831-60-0
intervention_candidates_unaccepted, candidates not yet reviewed
No candidate proposed.
EUCTR FRD. IMP Identification, item 1
INNCandidate match, not reviewed
Vinorelbine
intervention_candidates_unaccepted, candidates not yet reviewed
- CHEMBL553025 VINORELBINEChEMBL, name match, UNII InChIKey support. Candidate match, not reviewed.
EUCTR FRD. IMP Identification, item 5
CASCandidate match, not reviewed
71486-22-1
intervention_candidates_unaccepted, candidates not yet reviewed
- CHEMBL553025 VINORELBINEChEMBL, CAS to UNII InChIKey. Candidate match, not reviewed.
EUCTR FRD. IMP Identification, item 5
NameAmbiguous
Eribulin Mesylate
intervention_candidates_unaccepted, candidates not yet reviewed
- CHEMBL1683544 ERIBULIN MESYLATEChEMBL, label and synonym match. Candidate match, not reviewed.
ClinicalTrials.govInterventions, item 4
NameAmbiguous
Eribulin
intervention_candidates_unaccepted, candidates not yet reviewed
- CHEMBL1683590 ERIBULINChEMBL, label and synonym match. Candidate match, not reviewed.
ClinicalTrials.govInterventions, item 4

ChEMBL data is from http://www.ebi.ac.uk/chembl - the version of ChEMBL is chembl_37. CC BY-SA 3.0.

Across the programme

Twenty-one ways the records write it.

Search the served terms for datopotamab deruxtecan and its codes, and 56 studies answer, through 145 records. The release does not resolve programmes, so this is a search, shown as one, not a programme Atlas has assembled.

Terms searched: datopotamab, Dato-DXd, DS-1062, DS1062

Records, by registry

ClinicalTrials.gov: 49 records in 49 studies
CTIS: 32 records in 32 studies
EU Clinical Trials Register: 64 records in 14 studies

Studies stating each phase

Phase 113
Phase 230
Phase 320
Phase 41

A study that states more than one phase counts in each.

MeSH terms ClinicalTrials.gov assigns, by studies

D002289Carcinoma, Non-Small-Cell Lung22
D001943Breast Neoplasms21
D064726Triple Negative Breast Neoplasms9
D009362Neoplasm Metastasis7
D008175Lung Neoplasms4
D010190Pancreatic Neoplasms3
D010051Ovarian Neoplasms3
D001749Urinary Bladder Neoplasms3

MeSH 2026 data courtesy of the U.S. National Library of Medicine (NLM). NLM is not responsible for this product and does not endorse it.

Every term text that matched, with the studies that use it

Datopotamab deruxtecan38
Dato-DXd24
Datopotamab Deruxtecan14
DS-1062a10
Datopotamab Deruxtecan (Dato-DXd)6
Datopotamab deruxtecan (Dato-DXd, DS-1062a)5
Datopotamab deruxtecan (Dato-DXd)4
Dato-DXd, DS-1062a3
ADC of a MAb, MAAP-9001a, conjugated with a drug-linker, MAAA-1162a (datopotamab deruxtecan)2
DS-10622
(Dato-DXd, DS-1062a)1
datopotamab deruxtecan1
DS-1062; DS-1062a, Dato-DXd1
DS1062a1
Dato-DXd, Datroway1
Dato-DXd; DS-1062a1
Datopotamab Deruxtecan (Dato-DXd DS-1062a)1
Datopotamab deruxtecan + Durvalumab1
Datopotamab deruxtecan-dlnk (Dato-DXd)1
Datopotamab-Deruxtecan1
Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan1

One ChEMBL candidate, CHEMBL4297939, alone finds 49 of the 56 studies. The rest are found by their text, which is why Atlas keeps the text as well as the candidate.

Saved work

A saved landscape keeps its receipts.

Where saved landscapes are enabled for your account, reopen a comparison later with its question, evidence, and history intact.

The exact question you asked, and its scope
Which data release each record was read from, and its data-as-of date
Which records you included, with the evidence behind each one
What was missing, conflicting, or not searched
Refreshing creates a new version and leaves the one you saw as it was

Coverage and boundaries

What this page covers, and what Atlas won’t do.

Data as of

6 Oct 2026

Records

10 of 10, from 3 registries

Registries

ClinicalTrials.gov, CTIS, EUCTR

Outcome results

Not shown on this page

Built to compare across sources. This study shows three: ClinicalTrials.gov, CTIS and the EU Clinical Trials Register. Your account shows which sources are available to you.
Evidence first, analysis second. Records are retrieved and organized before any analysis runs. An analysis works only from the evidence you selected. It doesn’t browse sources or add records.
Missing stays missing. A statement Atlas does not map keeps its reason code. Anything this release does not read is labeled not collected yet, never as something the registry doesn’t report.
No clinical interpretation. Atlas does not make treatment recommendations, benefit-risk conclusions, efficacy rankings, or probability-of-success claims.

Questions

Small print, in plain words.

Is this a live search?

No. Everything on this page is read from Atlas, with data as of 6 Oct 2026. Nothing here runs a registry search or a model, and nothing you select is saved.

Why this study?

It is registered in three registries and in eight EU countries, so it shows what Atlas keeps when records overlap and disagree. It was not chosen for its results, and this page shows none.

Why are some values not mapped?

Atlas maps a statement to a shared category only through an exact published table. When none applies, the statement stays on the page with a reason code instead of being guessed into a category.

What does a real comparison add?

In Atlas you start from your own question, include the sources available to your account, and save the landscape with its evidence and history so you can reopen it later.

Take the next step

Start your first comparison.

Atlas Free includes three datasets and needs no card. Build a first landscape and export it with every row cited.